Marianne De Backer, Vir Biotechnology CEO

Vir's ear­ly Phase 2 he­pati­tis D da­ta show re­duc­tion, re­moval of virus with com­bo and monother­a­py

Vir’s chron­ic he­pati­tis D treat­ment re­duced the pres­ence of the virus RNA as well as nor­mal­ized cer­tain liv­er en­zyme lev­els across 24 weeks in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.